- Home
- JMM vs CUE Comparison
JMM vs CUE Comparison
Compare JMM & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMM | CUE |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.5M | 27.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | JMM | CUE |
|---|---|---|
| Price | $5.94 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 11.2K | ★ 350.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $5.68 | $0.23 |
| 52 Week High | $6.52 | $1.05 |
Technical Indicators
Market Signals| Indicator | JMM | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 27.67 | 46.02 |
| Support Level | N/A | $0.27 |
| Resistance Level | $6.24 | $0.36 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 0.00 | 40.65 |
Price Performance
Historical ComparisonAbout JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.